First Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA
November 05, 2015 at 08:37 AM EST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the first patient has received its investigational new drug, PEGPH20 in ...
